Stimulant psychosis: systematic review

被引:200
作者
Curran, C
Byrappa, N
McBride, A
机构
[1] Pendine Community Mental Hlth trust, Cardiff CF5 5BT, S Glam, Wales
[2] Rectory Ctr, Specialist Community Addict Serv, Oxford, England
关键词
D O I
10.1192/bjp.185.3.196
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Psychosis associated with stimulant use is an increasing problem, but there is little research evidence about the nature of the problem and its management. Aims To critically review the literature on stimulant psychosis and sensitisation, Method Systematic review of studies that have investigated stimulant use and psychosis in humans. The main outcome measures were increases in psychosis with stimulant use, and differences between stimulant users and non-users. Results Fifty-four studies met the inclusion criteria. Experimental studies show that a single dose of a stimulant drug can produce a brief increase in psychosis ratings (a 'response') in 50-70% of participants with schizophrenia and preexisting acute psychotic symptoms, unaffected by the presence of antipsychotic medication. Those with schizophrenia who do not have acute psychotic symptoms respond, but less frequently (30%). There has been little research into the longer-term effects of use. Conclusions Compliance with antipsychotic medication by someone with schizophrenia will not prevent a relapse or worsening of psychotic symptoms if stimulants are used. Low-dose antipsychotic treatment may be beneficial in stimulant users, to prevent sensitisation.
引用
收藏
页码:196 / 204
页数:9
相关论文
共 63 条
[1]  
Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761
[2]  
American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, P5
[3]   PARTIAL IMPROVEMENT IN NEGATIVE SCHIZOPHRENIC SYMPTOMS AFTER AMPHETAMINE [J].
ANGRIST, B ;
PESELOW, E ;
RUBINSTEIN, M ;
CORWIN, J ;
ROTROSEN, J .
PSYCHOPHARMACOLOGY, 1982, 78 (02) :128-130
[4]   AMPHETAMINE RESPONSE AND RELAPSE RISK AFTER DEPOT NEUROLEPTIC DISCONTINUATION [J].
ANGRIST, B ;
PESELOW, E ;
RUBINSTEIN, M ;
WOLKIN, A ;
ROTROSEN, J .
PSYCHOPHARMACOLOGY, 1985, 85 (03) :277-283
[5]   RESPONSES TO APOMORPHINE, AMPHETAMINE, AND NEUROLEPTICS IN SCHIZOPHRENIC SUBJECTS [J].
ANGRIST, B ;
ROTROSEN, J ;
GERSHON, S .
PSYCHOPHARMACOLOGY, 1980, 67 (01) :31-38
[6]   Selective sensitization to the psychosis-inducing effects of cocaine: A possible marker for addiction relapse vulnerability? [J].
Bartlett, E ;
Hallin, A ;
Chapman, B ;
Angrist, B .
NEUROPSYCHOPHARMACOLOGY, 1997, 16 (01) :77-82
[7]  
BRABBINS C, 1996, PSYCHIAT B, V20, P410, DOI DOI 10.1192/PB.20.7.410
[8]  
BRADY KT, 1991, J CLIN PSYCHIAT, V52, P509
[9]   Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"):: Psychomotor performance and subjective effects [J].
Camí, J ;
Farré, M ;
Mas, M ;
Roset, PN ;
Poudevida, S ;
Mas, A ;
San, L ;
de la Torre, R .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (04) :455-466
[10]  
CARPENTER MD, 1992, J CLIN PSYCHOPHARM, V12, P273